Termeer Symposium

The bi-annual Termeer Symposium, presented by the Henri and Belinda Termeer Center for Targeted Therapies, features discussions from leading experts on cutting-edge topics in personalized cancer medicine.

October 16, 2017 Event

The Transformational Potential of Liquid Biopsies and Blood-Based Biomarkers: Using Predictive Analytics to Inform Cancer Drug Development and Treatment Strategies

A Roundtable Panel Discussion presented by the Henri and Belinda Termeer Center for Targeted Therapies

October 16, 2017 | 5:30PM-8:00PM | Program
Liberty Hotel
215 Charles Street
Boston, MA 02114

Program Agenda

5:30PM - Registration
6:00PM - Welcome and Introductions
               - Panel Discussion
7:15PM - Interactive discussion with audience
8:00PM - Cocktail Reception



    • Keith Flaherty, MD

      Keith Flaherty

      Director, Henri and Belinda Termeer Center for Targeted Therapies
      Mass General Cancer Center

  • View Bio

    Dr. Flaherty is a Professor of Medicine at Harvard Medical School, Associate Physician of Medicine, Hematology/Oncology at Massachusetts General Hospital, and Director of the Henri and Belinda Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center. He is also the Deputy Chair for Biomarker Sciences and the Chair of the Developmental Therapeutics Committee in the Eastern Cooperative Oncology Group. Dr. Flaherty has served as principal investigator for numerous first-in-human clinical trials with novel, targeted therapies, including the first inhuman trials of the first prospectively developed selective BRAF inhibitors for metastatic melanoma.


  • Ryan Corcoran, MD, PhD

    Program Director, Tucker Gosnell Gastrointestinal Cancer Center
    Mass General Cancer Center

  • View Bio

    Dr. Corcoran is the Program Director of the Tucker Gosnell Gastrointestinal Cancer Center at the Mass General Cancer Center. As a researcher, he is focused both on targeted therapies for GI cancers, including colorectal and pancreatic cancers, as well as liquid biopsy analysis of circulating tumor DNA in the clinic. His lab’s research has involved understanding the determinants of resistance to RAF and MEK inhibitors in about 10% of colorectal cancers where oncogenic BRAF mutations are found; this work and investigating combination therapies in KRAS mutant cancers are internationally recognized.


    • Luis Diaz, MD

      Head of the Division of Solid Tumor Oncology
      Memorial Sloan Kettering

  • View Bio

    Dr. Diaz is a leading authority in oncology who has pioneered several genomic diagnostic and therapeutic approaches for cancer. He is head of the Division of Solid Tumor Oncology at the Memorial Sloan Kettering Cancer Center where he specializes in the treatment of advanced pancreatic and colorectal cancers. He is also founder of several entities that focus on genomic analyses of cancers including Inostics, PapGene and Personal Genome Diagnostics (PGDx). Dr. Diaz is involved in near-patient translational studies with the goal of bringing diagnostic and therapeutic studies to patients. His work has involved the clinical development of tumor-derived DNA as a biomarker for cancer screening, early detection, monitoring and measurement of early residual disease.

  • View Bio

    Dr. Engelman is Vice President and Global Head of Oncology Research at Novartis. He directs cancer drug discovery at the Novartis Institutes for BioMedical Research. Before joining Novartis, he was Director of the Center for Thoracic Oncology and Molecular Therapeutics at Massachusetts General Hospital, where he studied responses to targeted therapies and mechanisms of resistance in lung cancer. He was also an Associate Professor at Harvard Medical School.

  • View Bio

    Dr. Haber is the Director of the Mass General Cancer Center and the Kurt J. Isselbacher Professor of Oncology at Harvard Medical School. His laboratory interests have focused on the area of cancer genetics and targeted cancer therapies. His laboratory reported that lung cancers with epidermoid growth factor receptor (EGFR) mutations were uniquely sensitive to tyrosine kinase inhibitors that target this receptor. This served as a monumental shift in the treatment of non-small cell lung cancer and molecular targeted therapy in general. In collaboration with Dr. Mehmet Toner’s laboratory, Dr. Haber’s laboratory recently established the application of a novel microfluidic technology for quantifying and purifying Circulating Tumor Cells (CTCs) from the blood of patients with various epithelial cancers; having potentially profound implications for early diagnosis of cancer and for noninvasive molecular profiling of cancers during the course of therapy.

  • View Bio

    Dr. Stephens joined Foundation Medicine in March 2011, bringing more than a decade of experience in cancer genomics to the company. Dr. Stephens has authored numerous publications in Nature, Nature Genetics, Nature Medicine, Cell and other high-profile journals. Prior to joining Foundation Medicine, Dr. Stephens held various senior research positions during his 11-year tenure with the Cancer Genome Project at the Wellcome Trust Sanger Institute under the direction of Professor Michael Sir Stratton.

About the Symposium

The Termeer Symposium, sponsored by the Henri and Belinda Termeer Center for Targeted Therapies, was established in 2012 as an opportunity for scientists, physicians, biotechnology/pharmaceutical companies and venture capital executives to join together for an evening of education and collaboration. Henri Termeer envisioned that this forum would serve as a platform from which new ideas would germinate around a major theme and serve as a springboard for future research and directions. Several current research initiatives are a direct result of prior roundtable discussions.


  • Henri A. Termeer

    February 28, 1946 – May 12, 2017

Throughout his life, Mr. Termeer was dedicated to innovation in medical care, bringing both a creative and insightful vision, as well as profound compassion. As CEO of Genzyme, he championed personalized medicine for rare diseases, and as Trustee of Mass General, he contributed his wisdom and sharp intellect to the benefit of the entire institution.

The Henri and Belinda Termeer Center for Targeted Therapies was begun and sustained through Henri and Belinda’s vision and generosity and has meant access to early, breakthrough targeted and immunological therapies for hundreds of patients. His commitment to the Mass General Cancer Center was rooted in his deeply held belief that research and science could light the way for patients and that getting these discoveries to patients as quickly as possible was of paramount importance. Of equal importance was Henri’s unwavering conviction that innovative science that could impact one patient was of equal importance to the efforts that could impact many.

As a true friend and supporter of the Mass General Cancer Center, Henri Termeer brought to us passion and an inspiring, optimistic spirit. The Cancer Center will use the example he set to continue our commitment to ensuring that every patient is treated with the dedication and compassion that we would wish for our loved ones, and that our scientific research is pursued with that same passion and rigor.

Past Events


For more information regarding the Termeer Symposium, please contact:

Maida Broudo, M.A.
Project/Program Manager, Henri and Belinda Termeer Center for Targeted Therapies
Massachusetts General Hospital
Tel: 617-816-7789

Back to Top